480451-75-0

Basic information

• Product Name: 5-CHLORO-N,N-DIMETHYL-2-NITRO-BENZAMIDE
• Synonyms: 5-CHLORO-N,N-DIMETHYL-2-NITRO-BENZAMIDE;Benzamide, 5-chloro-N,N-dimethyl-2-nitro-
• CAS NO: 480451-75-0
• Molecular Formula: C₉H₉ClN₂O₃
• Molecular Weight: 228.63236
• EINECS: 604-604-1
• Mol File: 480451-75-0.mol

Chemical Properties

• Boiling Point: 399.4°C at 760 mmHg
• Flash Point: 195.3°C
• Appearance: /
• Density: 1.356g/cm³
• Vapor Pressure: 1.38E-06mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-CHLORO-N,N-DIMETHYL-2-NITRO-BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-N,N-DIMETHYL-2-NITRO-BENZAMIDE(480451-75-0)
• EPA Substance Registry System: 5-CHLORO-N,N-DIMETHYL-2-NITRO-BENZAMIDE(480451-75-0)

Safety Data

• Hazardous Substances Data: 480451-75-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5-CHLORO-N,N-DIMETHYL-2-NITRO-BENZAMIDE is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals, playing a crucial role in the development of new drugs and agricultural products.
Used in Dye and Pigment Production:
5-CHLORO-N,N-DIMETHYL-2-NITRO-BENZAMIDE is utilized in the production of dyes and pigments due to its nitro and chloro functional groups, which contribute to the color properties of these products.
Used in Research and Development:
5-CHLORO-N,N-DIMETHYL-2-NITRO-BENZAMIDE is employed as a building block in the preparation of organic compounds for research and development, aiding in the discovery and innovation of new chemical entities and materials.

InChI:InChI=1/C9H9ClN2O3/c1-11(2)9(13)7-5-6(10)3-4-8(7)12(14)15/h3-5H,1-2H3

Upstream product

• 506-59-2 N,N-dimethylammonium chloride 
• 2516-95-2 5-chloro-2-nitrobenzoic acid 
• 41994-44-9 5-chloro-2-nitrobenzoyl chloride 
• 124-40-3 dimethyl amine 

Downstream Products

• 594844-71-0 (3-dimethylcarbamoyl-4-nitrophenyl)acetic acid methyl ester 
• 594844-72-1 (4-amino-3-dimethylcarbamoylphenyl)acetic acid methyl ester 
• 594844-27-6 2-(3-(dimethylcarbamoyl)-4-(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-ylcarboxamido)phenyl)acetic acid 
• 1350468-91-5 methyl [3-(dimethylcarbamoyl)-4-({[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)phenyl]acetate 
• 1350468-90-4 ethyl 1R-({2-[3-(dimethylcarbamoyl)-4-({[4'-(trifluoromethyl)biphenyl-2-yl]carbonyl}amino)phenyl]acetoxy}methyl)-2-methyl-3-oxoisoindoline-1-carboxylate 
• 1350469-23-6 ethyl (1R)-1-({2-[3-(dimethylcarbamoyl)-4-nitrophenyl]acetoxy}methyl)-2-methyl-3-oxoisoindoline-1-carboxylate 
• 1350469-24-7 ethyl (1R)-1-({2-[4-amino-3-(dimethylcarbamoyl)phenyl]acetoxy}methyl)-2-methyl-3-oxoisoindoline-1-carboxylate 
• 1350468-87-9 diethyl 2-(4-amino-3-(dimethylcarbamoyl)phenyl)malonate 
• 1350469-51-0 2-(3-(dimethylcarbamoyl)-4-(6-methyl-4′-(trifluoromethyl)-[1,1′-biphenyl]-2-carboxamido)phenyl)acetic acid 
• 1350469-50-9 diethyl 2-(3-(dimethylcarbamoyl)-4-(6-methyl-4′-(trifluoromethyl)-[1,1′-biphenyl]-2-carboxamido)phenyl)malonate 
• 1350468-88-0 diethyl 2-(3-(dimethylcarbamoyl)-4-nitrophenyl)malonate 
• 1403353-72-9 N,N-dimethyl-2-nitro-5-(piperazin-1-yl)benzamide 
• 1350468-85-7 [3-(dimethylcarbamoyl)-4-nitrophenyl]acetic acid 
• 1350469-25-8 ethyl (1R)-1-({2-[3-(dimethylcarbamoyl)-4-{[(4'-isopropoxybiphenyl-2-yl)carbonyl]amino}phenyl]acetoxy}methyl)-2-methyl-3-oxoisoindoline-1-carboxylate 

Relevant articles and documents

Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold

A series of (1H-benzo[d][1,2,3]triazol-1-yl)(4-benzylpiperazin-1-yl) methanones and of (1H-benzo[d][1,2,3]triazol-1-yl)(4-phenylpiperazin-1-yl) methanones has been prepared and tested on human fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL). In the benzylpiperazinyl series, compound 29 (ML30) exhibited an IC50 value of 0.54 nM on MAGL, combined with a 1000-fold selectivity versus FAAH, while compounds 11 and 16 acted as potent dual FAAH-MAGL inhibitors (IC50 50 values against MAGL in the nanomolar range, whilst being between one and two orders of magnitude less potent on the FAAH, while compounds 31 and 32 were potent FAAH inhibitors (IC50 20 nM) and over 12-fold selective versus MAGL. The key structural determinants driving the structure-activity relationships were explored by the minimization of the inhibitors inside the active site of both enzymes.

2-PHENYL BENZOYLAMIDES

Compounds of Formula I that inhibit microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion and their uses in the treatment of diseases linked thereto in animals are described herein.

Ester derivatives and medicinal use thereof

The present invention relates to an ester represented by the formula [1]: or its pharmaceutically acceptable salt, or use of the same. The compound represented by the formula [1] or its pharmaceutically acceptable salt is useful as an agent for the treatment or prophylaxis of hyperlipidemia or the like, since it disappears very rapidly in the living body and has an excellent MTP inhibitory activity.

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

ESTER COMPOUND AND MEDICINAL USE THEREOF

A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1") (wherein ???R1 and R2 are each hydrogen atom or optionally substituted aryl, etc.; ???X is -COO- or -CON(R10)-; ???R3 and R4 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; ???R5, R6 and R7 are each hydrogen atom, C1-C6 alkyl or C1-C6 alkoxy, etc.; ???R8 and R9 are each independently hydrogen atom, C1-C6 alkyl, -CON(R18)(R19) or -COO(R20), etc.; ???ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.; ???Alk1 and Alk2 are each independently alkanediyl, etc.; ???l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either. The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.